New drug delivery system for treating osteoarthritis pain
Bioerodible corticosteroid microparticle-drug as an intra-articular drug delivery system for osteoarthritis therapy
['FUNDING_R21'] · UNIVERSITY OF MICHIGAN AT ANN ARBOR · NIH-10709663
This study is testing a new way to deliver medicine directly to sore joints for people with osteoarthritis, using tiny particles that slowly release a corticosteroid to help reduce pain and swelling while aiming to cause fewer side effects.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MICHIGAN AT ANN ARBOR (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-10709663 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel drug delivery system using bioerodible corticosteroid microparticles to treat osteoarthritis (OA). The approach aims to provide a controlled release of corticosteroids directly into the affected joints, potentially reducing pain and inflammation over an extended period. By utilizing a unique fabrication method, the microparticles are designed to consist primarily of the active drug, minimizing side effects associated with traditional treatments. Patients suffering from chronic OA pain may find this innovative treatment beneficial.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are experiencing symptomatic osteoarthritis.
Not a fit: Patients with osteoarthritis who are not experiencing significant pain or inflammation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve pain management and quality of life for patients with osteoarthritis.
How similar studies have performed: Previous research has shown promise in using intra-articular corticosteroids for osteoarthritis, but this specific approach with bioerodible microparticles is novel.
Where this research is happening
ANN ARBOR, UNITED STATES
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MAERZ, TRISTAN — UNIVERSITY OF MICHIGAN AT ANN ARBOR
- Study coordinator: MAERZ, TRISTAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.